BiotechTube
FUJIFILM Pharma

FUJIFILM Pharma

Lexington, United States· Est.
fujifilmpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

FUJIFILM Pharmaceuticals U.S.A., Inc., founded in 2004, is a U.S.-based subsidiary of FUJIFILM Corporation that operates a hybrid business model combining proprietary drug development with a specialized CDMO service. Its core technology platform centers on advanced drug delivery systems, including liposomes and LNPs, which it applies to its internal pipeline of oncology candidates and offers as a service to external partners. The company is advancing several clinical-stage assets, has a recently approved antiviral, and is positioned at the intersection of the growing precision medicine and advanced drug delivery markets.

OncologyInfectious Diseases

Technology Platform

Advanced drug delivery platform specializing in liposomal and lipid nanoparticle (LNP) formulations, including a proprietary ionizable lipid library for nucleic acid delivery. Capabilities span from formulation design to commercial-scale GMP manufacturing, with integrated mRNA expertise.

Opportunities

The company is well-positioned to capitalize on the booming demand for advanced drug delivery CDMO services, particularly for mRNA and LNP-based therapies.
Its proprietary ionizable lipid library represents a significant licensing opportunity in the growing genetic medicine field.
Success in its ongoing Phase 2 combination trial with pembrolizumab could validate its platform and lead to further high-value partnerships.

Risk Factors

The internal pipeline faces inherent clinical trial risks, where failure in late-stage studies would be a major setback.
The CDMO business operates in an intensely competitive landscape, requiring constant innovation to maintain an edge.
As a subsidiary, its strategic direction and resource allocation are ultimately dependent on the priorities of its parent corporation.

Competitive Landscape

In the CDMO space, it competes with large players like Lonza, Catalent, and Thermo Fisher Scientific, as well as specialized lipid-focused CDMOs. In proprietary drug development, it competes with other oncology-focused biotechs and companies developing improved formulations of chemotherapeutics. Its ionizable lipid library faces competition from dedicated lipid technology firms such as Acuitas Therapeutics and Genevant Sciences.

More companies in Drug Delivery & Formulation →More companies in United States →